Liquid biopsy has moved from a research promise to a crowded commercial category. Published market estimates differ widely on size (from roughly USD 2.6 billion to over USD 11 billion for 2025, depending on scope), but most forecasts agree on double-digit annual growth. The harder lesson for developers is that analytical and clinical validation no longer guarantee a viable product. Reimbursement, regulatory pathway, physician workflow and competitor timing now decide who scales. This article explains how a diagnostics innovator structured a commercial readiness assessment for its next-generation liquid biopsy test, and what other developers can borrow from the approach.
What Is Commercial Readiness in Liquid Biopsy?
Commercial readiness is the evidence-based judgment of whether a validated test can win coverage, clinician adoption and sustainable volume in a specific indication and market. For liquid biopsy, it combines five questions: Is the clinical utility defensible? Is the regulatory route clear? Will payers cover it? Will physicians order it? Can it differentiate against tests already in the clinic?
A test can answer the first question and fail the other four. That gap is where most go-to-market risk sits.
Why the Market Context Changed
Three shifts reshaped the assessment.
Screening became real. Guardant Health’s Shield received FDA approval in July 2024 as the first blood test for primary colorectal cancer screening in average-risk adults aged 45 and older, and Medicare covers it. CMS granted it Advanced Diagnostic Laboratory Test status in March 2025, which sets a path to Medicare pricing based on private payer rates. Approval opened the category; payer and workflow work determines volume.
Multi-cancer detection approached a decision point. GRAIL submitted the final module of its Galleri premarket approval application in January 2026. An FDA advisory panel met on September 23, 2026 and voted in favor, though the effectiveness vote was a narrow 6 to 4, and critics raised concerns about sensitivity in stage I cancers and the absence of mortality data. A final FDA decision was still pending at the time of writing. Separately, legislation signed on February 3, 2026 creates a Medicare benefit category for FDA-approved multi-cancer early detection tests, with coverage beginning in 2028.
Regulation shifted for lab-developed tests. A federal court vacated FDA’s 2024 laboratory-developed test rule in March 2025, and FDA formally rescinded it that September. Developers can still pursue CLIA-based launches, but payers and guideline bodies increasingly look for strong evidence regardless of the regulatory route.
How the Assessment Was Structured
The innovator evaluated five lenses, each answered with primary and secondary evidence rather than internal assumptions.
| Lens | Core question | Evidence used |
|---|---|---|
| Clinical utility | Does the result change a treatment or screening decision? | Trial readouts, guidelines, congress data |
| Regulatory pathway | PMA, 510(k)/De Novo, or CLIA laboratory-developed test? | FDA precedent, advisory committee outcomes |
| Payer and reimbursement | What evidence do payers and Medicare contractors require? | Coverage policies, payer interviews |
| Physician adoption | Who orders it, and what blocks ordering? | KOL and community clinician interviews |
| Competitive position | Where does it differ from tests already used? | Competitor tracking, pipeline intelligence |
Clinical utility and evidence positioning
Minimal residual disease (MRD) testing shows why utility matters more than sensitivity alone. Natera’s Signatera gained momentum after the Phase III IMvigor011 bladder cancer trial used it to select patients for adjuvant immunotherapy. By contrast, the DYNAMIC-III trial of ctDNA-guided chemotherapy de-escalation in colon cancer did not meet its non-inferiority endpoint, although investigators noted ctDNA still informs individual risk discussions. The assessment treated such trials as signals of which claims clinicians and payers will accept.
Reimbursement and payer readiness
Payer evidence requirements vary by use case. Signatera’s coverage has expanded indication by indication through Medicare contractor determinations, including colorectal and non-small cell lung cancer surveillance. Natera has also submitted its tissue-free Latitude assay for colorectal cancer reimbursement review. The takeaway for developers: coverage is earned per indication, so launch sequencing should follow the strength of payer-grade evidence, not the size of the addressable population.
Physician adoption and KOL validation
Guidelines and ordering behavior follow trusted experts. The assessment used structured interviews with oncologists, pathologists and gastroenterology specialists to test whether the clinical story survives real workflows: sample collection, turnaround time, result interpretation and follow-up. SPER’s primary intelligence and KOL expert network programs support this kind of validation.
Competitive timing
Competitors move on regulatory and reimbursement milestones, so the team tracked congress presentations, trial readouts and coverage announcements continuously rather than as a one-time snapshot.
Practical Use Cases
- Screening (colorectal, multi-cancer): Adherence and follow-up colonoscopy pathways matter as much as sensitivity. Guardant reports a 93% completion rate across its first 100,000 Shield orders, a company-reported figure.
- MRD and recurrence monitoring: Utility depends on whether a positive result leads to a different treatment.
- Therapy selection: Value hinges on turnaround time versus tissue testing and on integration with oncology workflows.
Industry Insight: What Leading Companies Signal
Leaders are converging on a pattern: secure a regulatory milestone, then invest heavily in coverage across payer types (Medicare, Medicare Advantage, TRICARE, Veterans Affairs community care) and in distribution through partners such as Quest Diagnostics. Evidence strategy is becoming indication-specific, and policy is rewarding developers who can show clinical benefit rather than technical performance alone. Expect the next competitive battleground to be real-world evidence and head-to-head positioning between blood-based and stool-based or imaging-based alternatives.
Frequently Asked Questions
Conclusion
Commercial readiness is a question about adoption, not just accuracy. The innovator’s assessment worked because it tested five lenses together and relied on primary evidence from experts and payers alongside market data. As screening, MRD and multi-cancer detection mature, developers who validate demand early can sequence launches with far less risk.
Assess readiness for your own liquid biopsy program
To assess readiness for your own liquid biopsy program, talk to SPER Market Research about primary intelligence and expert-led validation.
Talk to SPER Market Research



















